CN117205266A - Pharmaceutical composition for reducing ionizing radiation hazard - Google Patents
Pharmaceutical composition for reducing ionizing radiation hazard Download PDFInfo
- Publication number
- CN117205266A CN117205266A CN202311415105.9A CN202311415105A CN117205266A CN 117205266 A CN117205266 A CN 117205266A CN 202311415105 A CN202311415105 A CN 202311415105A CN 117205266 A CN117205266 A CN 117205266A
- Authority
- CN
- China
- Prior art keywords
- parts
- pharmaceutical composition
- ionizing radiation
- drying
- reducing
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 title claims abstract description 51
- 230000005865 ionizing radiation Effects 0.000 title claims abstract description 39
- 230000006378 damage Effects 0.000 claims abstract description 30
- YEFOAORQXAOVJQ-RZFZLAGVSA-N schisandrol a Chemical compound C1[C@H](C)[C@@](C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-RZFZLAGVSA-N 0.000 claims abstract description 30
- 150000004676 glycans Chemical class 0.000 claims abstract description 20
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 20
- 239000005017 polysaccharide Substances 0.000 claims abstract description 20
- 241000405414 Rehmannia Species 0.000 claims abstract description 17
- 244000248557 Ophiopogon japonicus Species 0.000 claims abstract description 15
- YEFOAORQXAOVJQ-UHFFFAOYSA-N wuweizischun A Natural products C1C(C)C(C)(O)CC2=CC(OC)=C(OC)C(OC)=C2C2=C1C=C(OC)C(OC)=C2OC YEFOAORQXAOVJQ-UHFFFAOYSA-N 0.000 claims abstract description 15
- 239000013078 crystal Substances 0.000 claims abstract description 14
- 229930193195 schizandrin Natural products 0.000 claims abstract description 14
- 229930195210 Ophiopogon Natural products 0.000 claims abstract description 11
- HOMSOWZTBJWNHP-UHFFFAOYSA-N 5-chlorothiadiazole Chemical compound ClC1=CN=NS1 HOMSOWZTBJWNHP-UHFFFAOYSA-N 0.000 claims abstract description 9
- VDYCLYGKCGVBHN-UHFFFAOYSA-N pachymaic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC(=C)C(C)C)C(O)=O)C(O)CC21C VDYCLYGKCGVBHN-UHFFFAOYSA-N 0.000 claims abstract description 9
- SRDNLMOBFKJOSD-UHFFFAOYSA-N pachymic acid Natural products CC12CCC(OC(C)=O)C(C)(C)C1CCC1=C2CCC2(C)C(C(CCC=C(C)C)C(O)=O)C(O)CC21C SRDNLMOBFKJOSD-UHFFFAOYSA-N 0.000 claims abstract description 9
- 239000000284 extract Substances 0.000 claims description 22
- 239000000843 powder Substances 0.000 claims description 21
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 21
- 239000000203 mixture Substances 0.000 claims description 19
- 239000003814 drug Substances 0.000 claims description 18
- 238000001035 drying Methods 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 14
- 238000002156 mixing Methods 0.000 claims description 13
- 239000000706 filtrate Substances 0.000 claims description 11
- 238000002791 soaking Methods 0.000 claims description 11
- 239000000463 material Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 8
- 238000010298 pulverizing process Methods 0.000 claims description 7
- 241000233855 Orchidaceae Species 0.000 claims description 5
- 229930182470 glycoside Natural products 0.000 claims description 5
- 150000002338 glycosides Chemical class 0.000 claims description 5
- 239000002552 dosage form Substances 0.000 claims description 4
- 238000001914 filtration Methods 0.000 claims description 4
- 241000588653 Neisseria Species 0.000 claims description 3
- 239000004480 active ingredient Substances 0.000 claims description 3
- 239000002245 particle Substances 0.000 claims description 3
- 239000006187 pill Substances 0.000 claims description 3
- 238000009835 boiling Methods 0.000 claims description 2
- 239000002775 capsule Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 239000007788 liquid Substances 0.000 claims description 2
- 238000001694 spray drying Methods 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 238000001291 vacuum drying Methods 0.000 claims description 2
- 230000000694 effects Effects 0.000 abstract description 23
- 208000027418 Wounds and injury Diseases 0.000 abstract description 9
- 208000014674 injury Diseases 0.000 abstract description 9
- 241000699670 Mus sp. Species 0.000 abstract description 7
- 210000000265 leukocyte Anatomy 0.000 abstract description 7
- 210000002798 bone marrow cell Anatomy 0.000 abstract description 6
- 230000008439 repair process Effects 0.000 abstract description 4
- 230000009286 beneficial effect Effects 0.000 abstract description 3
- 230000001737 promoting effect Effects 0.000 abstract description 3
- 229940126680 traditional chinese medicines Drugs 0.000 abstract description 3
- 239000002131 composite material Substances 0.000 abstract description 2
- 230000000052 comparative effect Effects 0.000 description 27
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 238000001959 radiotherapy Methods 0.000 description 10
- 241000213006 Angelica dahurica Species 0.000 description 6
- 244000197580 Poria cocos Species 0.000 description 6
- 235000008599 Poria cocos Nutrition 0.000 description 6
- 208000019155 Radiation injury Diseases 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 230000005855 radiation Effects 0.000 description 6
- 238000002474 experimental method Methods 0.000 description 5
- 238000012360 testing method Methods 0.000 description 5
- 239000003053 toxin Substances 0.000 description 5
- 231100000765 toxin Toxicity 0.000 description 5
- KSEBMYQBYZTDHS-HWKANZROSA-M (E)-Ferulic acid Natural products COC1=CC(\C=C\C([O-])=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-M 0.000 description 4
- 229930091371 Fructose Natural products 0.000 description 4
- 239000005715 Fructose Substances 0.000 description 4
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 4
- 241001619461 Poria <basidiomycete fungus> Species 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 208000031971 Yin Deficiency Diseases 0.000 description 4
- 229940107666 astragalus root Drugs 0.000 description 4
- 230000007812 deficiency Effects 0.000 description 4
- 235000001785 ferulic acid Nutrition 0.000 description 4
- KSEBMYQBYZTDHS-HWKANZROSA-N ferulic acid Chemical compound COC1=CC(\C=C\C(O)=O)=CC=C1O KSEBMYQBYZTDHS-HWKANZROSA-N 0.000 description 4
- 229940114124 ferulic acid Drugs 0.000 description 4
- KSEBMYQBYZTDHS-UHFFFAOYSA-N ferulic acid Natural products COC1=CC(C=CC(O)=O)=CC=C1O KSEBMYQBYZTDHS-UHFFFAOYSA-N 0.000 description 4
- 230000001717 pathogenic effect Effects 0.000 description 4
- 210000005259 peripheral blood Anatomy 0.000 description 4
- 239000011886 peripheral blood Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- QURCVMIEKCOAJU-UHFFFAOYSA-N trans-isoferulic acid Natural products COC1=CC=C(C=CC(O)=O)C=C1O QURCVMIEKCOAJU-UHFFFAOYSA-N 0.000 description 4
- SMDOOINVMJSDPS-UHFFFAOYSA-N Astragaloside Natural products C1=C(O)C(OC)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)OC2C(C(OC3C(C(O)C(O)C(CO)O3)O)C(O)C(CO)O2)O)=C1 SMDOOINVMJSDPS-UHFFFAOYSA-N 0.000 description 3
- 241000132012 Atractylodes Species 0.000 description 3
- 244000303040 Glycyrrhiza glabra Species 0.000 description 3
- 235000006200 Glycyrrhiza glabra Nutrition 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 206010028980 Neoplasm Diseases 0.000 description 3
- 240000004371 Panax ginseng Species 0.000 description 3
- 235000005035 Panax pseudoginseng ssp. pseudoginseng Nutrition 0.000 description 3
- 235000003140 Panax quinquefolius Nutrition 0.000 description 3
- 241000405911 Rehmannia glutinosa Species 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- QMNWISYXSJWHRY-XWJCTJPOSA-N astragaloside Chemical compound O1[C@H](C(C)(O)C)CC[C@]1(C)[C@@H]1[C@@]2(C)CC[C@]34C[C@]4(CC[C@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)CO4)O)C4(C)C)C4[C@@H](O[C@H]4[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O4)O)CC3[C@]2(C)C[C@@H]1O QMNWISYXSJWHRY-XWJCTJPOSA-N 0.000 description 3
- 210000001185 bone marrow Anatomy 0.000 description 3
- 201000011510 cancer Diseases 0.000 description 3
- 210000004027 cell Anatomy 0.000 description 3
- 238000011156 evaluation Methods 0.000 description 3
- 235000008434 ginseng Nutrition 0.000 description 3
- 230000001965 increasing effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000002285 radioactive effect Effects 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000007873 sieving Methods 0.000 description 3
- 239000007787 solid Substances 0.000 description 3
- 241001061264 Astragalus Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 206010011224 Cough Diseases 0.000 description 2
- 229920000858 Cyclodextrin Polymers 0.000 description 2
- 241000096284 Gynochthodes officinalis Species 0.000 description 2
- 235000017443 Hedysarum boreale Nutrition 0.000 description 2
- 235000007858 Hedysarum occidentale Nutrition 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- 241000112528 Ligusticum striatum Species 0.000 description 2
- 241000699666 Mus <mouse, genus> Species 0.000 description 2
- 244000236658 Paeonia lactiflora Species 0.000 description 2
- 235000008598 Paeonia lactiflora Nutrition 0.000 description 2
- 238000010521 absorption reaction Methods 0.000 description 2
- 235000006533 astragalus Nutrition 0.000 description 2
- 210000001124 body fluid Anatomy 0.000 description 2
- 239000010839 body fluid Substances 0.000 description 2
- 150000001875 compounds Chemical class 0.000 description 2
- 239000012153 distilled water Substances 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 235000013399 edible fruits Nutrition 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 230000002496 gastric effect Effects 0.000 description 2
- 239000001947 glycyrrhiza glabra rhizome/root Substances 0.000 description 2
- 210000000777 hematopoietic system Anatomy 0.000 description 2
- 230000011132 hemopoiesis Effects 0.000 description 2
- 210000000987 immune system Anatomy 0.000 description 2
- 230000001535 kindling effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000003672 processing method Methods 0.000 description 2
- 239000002994 raw material Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 235000014347 soups Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 230000001629 suppression Effects 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 210000004233 talus Anatomy 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 210000001835 viscera Anatomy 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 description 1
- ODEHMIGXGLNAKK-OESPXIITSA-N 6-kestotriose Chemical group O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@@H]1[C@@H](O)[C@H](O)[C@](CO)(O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 ODEHMIGXGLNAKK-OESPXIITSA-N 0.000 description 1
- 241000206501 Actaea <angiosperm> Species 0.000 description 1
- 241000049624 Alisma plantago-aquatica subsp. orientale Species 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000202726 Bupleurum Species 0.000 description 1
- 244000223760 Cinnamomum zeylanicum Species 0.000 description 1
- 206010010774 Constipation Diseases 0.000 description 1
- 241000209020 Cornus Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 235000002722 Dioscorea batatas Nutrition 0.000 description 1
- 235000006536 Dioscorea esculenta Nutrition 0.000 description 1
- 240000001811 Dioscorea oppositifolia Species 0.000 description 1
- 235000003416 Dioscorea oppositifolia Nutrition 0.000 description 1
- 239000001116 FEMA 4028 Substances 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 241000830535 Ligustrum lucidum Species 0.000 description 1
- 241000234280 Liliaceae Species 0.000 description 1
- 244000241838 Lycium barbarum Species 0.000 description 1
- 235000015459 Lycium barbarum Nutrition 0.000 description 1
- 235000015468 Lycium chinense Nutrition 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001212279 Neisseriales Species 0.000 description 1
- 206010068319 Oropharyngeal pain Diseases 0.000 description 1
- 235000002789 Panax ginseng Nutrition 0.000 description 1
- 201000007100 Pharyngitis Diseases 0.000 description 1
- 241000013557 Plantaginaceae Species 0.000 description 1
- 241000222640 Polyporus Species 0.000 description 1
- 206010039424 Salivary hypersecretion Diseases 0.000 description 1
- 208000013738 Sleep Initiation and Maintenance disease Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229930013930 alkaloid Natural products 0.000 description 1
- 150000003797 alkaloid derivatives Chemical class 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- JKOQGQFVAUAYPM-UHFFFAOYSA-N amifostine Chemical compound NCCCNCCSP(O)(O)=O JKOQGQFVAUAYPM-UHFFFAOYSA-N 0.000 description 1
- 229960001097 amifostine Drugs 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 208000007502 anemia Diseases 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- WHGYBXFWUBPSRW-FOUAGVGXSA-N beta-cyclodextrin Chemical compound OC[C@H]([C@H]([C@@H]([C@H]1O)O)O[C@H]2O[C@@H]([C@@H](O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O[C@H]3O[C@H](CO)[C@H]([C@@H]([C@H]3O)O)O3)[C@H](O)[C@H]2O)CO)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@@H]3O[C@@H]1CO WHGYBXFWUBPSRW-FOUAGVGXSA-N 0.000 description 1
- 235000011175 beta-cyclodextrine Nutrition 0.000 description 1
- 229960004853 betadex Drugs 0.000 description 1
- 238000004820 blood count Methods 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- JJWKPURADFRFRB-UHFFFAOYSA-N carbonyl sulfide Chemical compound O=C=S JJWKPURADFRFRB-UHFFFAOYSA-N 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 235000017803 cinnamon Nutrition 0.000 description 1
- UFULAYFCSOUIOV-UHFFFAOYSA-N cysteamine Chemical compound NCCS UFULAYFCSOUIOV-UHFFFAOYSA-N 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 238000002059 diagnostic imaging Methods 0.000 description 1
- FPAFDBFIGPHWGO-UHFFFAOYSA-N dioxosilane;oxomagnesium;hydrate Chemical compound O.[Mg]=O.[Mg]=O.[Mg]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O.O=[Si]=O FPAFDBFIGPHWGO-UHFFFAOYSA-N 0.000 description 1
- 208000017574 dry cough Diseases 0.000 description 1
- 238000004043 dyeing Methods 0.000 description 1
- 230000004064 dysfunction Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000000686 essence Substances 0.000 description 1
- 229960005309 estradiol Drugs 0.000 description 1
- 229930182833 estradiol Natural products 0.000 description 1
- 238000000556 factor analysis Methods 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- LPLVUJXQOOQHMX-QWBHMCJMSA-N glycyrrhizinic acid Chemical compound O([C@@H]1[C@@H](O)[C@H](O)[C@H](O[C@@H]1O[C@@H]1C([C@H]2[C@]([C@@H]3[C@@]([C@@]4(CC[C@@]5(C)CC[C@@](C)(C[C@H]5C4=CC3=O)C(O)=O)C)(C)CC2)(C)CC1)(C)C)C(O)=O)[C@@H]1O[C@H](C(O)=O)[C@@H](O)[C@H](O)[C@H]1O LPLVUJXQOOQHMX-QWBHMCJMSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 208000013403 hyperactivity Diseases 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 206010022437 insomnia Diseases 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 229920005610 lignin Polymers 0.000 description 1
- 235000011477 liquorice Nutrition 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 229960003151 mercaptamine Drugs 0.000 description 1
- 235000013336 milk Nutrition 0.000 description 1
- 239000008267 milk Substances 0.000 description 1
- 210000004080 milk Anatomy 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 230000008506 pathogenesis Effects 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 150000003904 phospholipids Chemical class 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002335 preservative effect Effects 0.000 description 1
- 208000037920 primary disease Diseases 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 239000001397 quillaja saponaria molina bark Substances 0.000 description 1
- 239000000941 radioactive substance Substances 0.000 description 1
- 208000026451 salivation Diseases 0.000 description 1
- 229930182490 saponin Natural products 0.000 description 1
- 150000007949 saponins Chemical class 0.000 description 1
- 230000002000 scavenging effect Effects 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000009924 shiquandabu Substances 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 210000000952 spleen Anatomy 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 210000001562 sternum Anatomy 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229940037128 systemic glucocorticoids Drugs 0.000 description 1
- 230000035922 thirst Effects 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 208000037816 tissue injury Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
Abstract
The invention relates to a pharmaceutical composition for reducing the harm of ionizing radiation, belonging to the technical field of traditional Chinese medicines. The composite material consists of the following components in parts by weight: 570-630 parts of prepared rehmannia root, 4-14 parts of crystal lanoside, 17-27 parts of Nernst sugar, 60-80 parts of ophiopogon polysaccharide, 75-95 parts of pachyman, 1-5 parts of pachymic acid and 1-3 parts of schizandrin. The pharmaceutical composition has the advantages of promoting the increase of the peripheral blood leucocyte number of mice injured by ionizing radiation, reducing the micronucleus number of bone marrow cells, being beneficial to the organism repair of injury caused by ionizing radiation and having the effect of reducing the harm of ionizing radiation.
Description
Technical Field
The invention belongs to the technical field of traditional Chinese medicines, and particularly relates to a pharmaceutical composition for reducing the harm of ionizing radiation.
Background
Ionizing radiation refers to radiation that carries energy sufficient to ionize atoms or molecules of matter, including cosmic rays, X-rays, and radiation from radioactive matter. There are two main sources of ionizing radiation: one is natural radiation, air and water from the universe and earth's surface, radioactive substances from the human body; the other is artificial radiation, including optical radiology in the medical field, medical imaging and radiation therapy. Systemic or local tissue damage of the body due to exposure to ionizing radiation is called ionizing radiation damage. The main source of ionizing radiation injury is the radiation therapy of malignant tumor, when the radioactive rays kill tumor cells, certain injury is caused to surrounding normal tissues, and the radioactive injury is caused to a plurality of systems of an organism, wherein the most common damage is the damage to the hematopoietic system and the immune system, and the damage is mainly caused by bone marrow suppression, so that the risks of anemia and hemorrhage are obviously increased, the immune function is reduced, the complications are increased, and the life quality of patients is seriously influenced.
At present, aiming at ionizing radiation injury, western medicine treatment mostly adopts large-dose antibiotics and glucocorticoids, and chemical synthesis substances such as cysteamine, amifostine, estradiol and the like, so that the curative effect is not ideal, the toxic and side effects are large, and the medicine cannot be used for a long time. In recent years, many scholars research shows that the traditional Chinese medicine can improve the life quality of radiotherapy patients, prolong the life time and have good protection effect on damage caused by radiotherapy. The compatibility of various traditional Chinese medicines can regulate spleen and stomach deficiency caused by radiotherapy and effectively prevent bone marrow suppression. It is reported that the traditional Chinese medicine Shiquandabu decoction (prescription composition: chinese angelica, ligusticum wallichii, white peony root, prepared rehmannia root, ginseng, white atractylodes rhizome, poria cocos, honey-fried licorice root, astragalus root and cinnamon), the eight delicacies decoction (prescription composition: ginseng, white atractylodes rhizome, white poria cocos, chinese angelica, ligusticum wallichii, white peony root, prepared rehmannia root and liquorice, etc.), the mixture for nourishing the healthy energy (prescription composition: red ginseng, astragalus root, wolfberry fruit, glossy privet fruit, polyporus and poria cocos), the decoction for invigorating the middle-jiao and Qi (prescription composition: astragalus root, honey-fried licorice root, ginseng, chinese angelica, orange peel, cimicifuga rhizome, bupleurum root and white atractylodes rhizome), the decoction for nourishing the blood (prescription composition: astragalus root and Chinese angelica), the pill of six-ingredient rehmannia root (prescription composition: prepared rehmannia root, white cornus, moutan bark, chinese yam, poria cocos and alisma orientalis) have better effects of improving and preventing and treating the injuries caused by radiation. Some Chinese medicinal materials such as polysaccharide, alkaloid, saponin, volatile oil, coumarin, etc. have effects of scavenging free radicals, promoting granulocyte hematopoiesis, increasing leukocyte, enhancing immunity, and repairing hematopoiesis tissue injury.
From the aspect of traditional Chinese medicine etiology, ionizing radiation can penetrate through fur, mouth and nose and orifices to invade human bodies to damage viscera, cause viscera dysfunction and imbalance of qi, blood and yin and yang, and the induced pathological evolution process is matched with pathogenic characteristics of toxin, so that the traditional Chinese medicine can be regarded as an external toxin. Meanwhile, the ionizing radiation has high energy, strong heat source property and penetrating power, and releases a large amount of energy when in play, so that toxin and pathogenic fire can be regarded as a fire toxin and pathogenic heat toxin according to the action characteristics. The primary pathogenesis is fire, blood stasis and deficiency, and the primary disease is that the body is 'deficiency of body fluid and blood' and pathogenic heat is generated internally, and fire is excessive due to yin deficiency and dryness-heat is difficult to endure. The formula of the fire-inducing decoction is in the definition of Qing dynasty Chen Shiduo, and the recipe comprises the following medicines: radix rehmanniae Preparata, radix Morindae officinalis, poria, radix Ophiopogonis, and radix Schisandrae Bicoloris. The fire-inducing decoction is suitable for yin deficiency and fire hyperactivity due to yin deficiency and internal yang heat by nourishing yin to reduce deficiency fire, inducing fire to return to the original position to coordinate yin and yang. The applicant has studied the mechanism of action of the kindling soup for preventing and treating ionizing radiation injury [ Zhou Lihui, etc. ] based on network pharmacology [ J ]. Specialty research, 2022, 44 (4): 44-52.].
Disclosure of Invention
The invention provides a pharmaceutical composition for reducing the harm of ionizing radiation, and aims to provide a pharmaceutical composition for reducing ionizing radiation injury and a pharmaceutical thereof, wherein the pharmaceutical composition has definite components and better effect. The invention searches relevant effective components through intensive research on the formula of the ignition decoction, and develops a pharmaceutical composition with definite components and better effect and capable of reducing ionizing radiation injury. The application of the pharmaceutical composition and the medicine thereof effectively helps the organism repair the organism injury caused by ionizing radiation and promotes the organism to recover as soon as possible; can be used for reducing ionizing radiation injury and reducing side effects of cancer radiotherapy.
The technical scheme adopted by the invention is as follows: the composite material consists of the following components in parts by weight:
570-630 parts of prepared rehmannia root, 4-14 parts of crystal lanoside, 17-27 parts of Nernst sugar, 60-80 parts of ophiopogon polysaccharide, 75-95 parts of pachyman, 1-5 parts of pachymic acid and 1-3 parts of schizandrin.
The preparation method of the ophiopogon japonicus polysaccharide comprises the following steps: pulverizing radix Ophiopogonis to obtain radix Ophiopogonis powder with particle size of 120-180 meshes, soaking in water: the mass volume ratio of the dwarf lilyturf tuber powder to the water is 1:8-16 g/mL, soaking for 0.5-2h, decocting at 90-100deg.C for 2-4 times for 0.5-2h, separating filtrate, concentrating, and drying to obtain radix Ophiopogonis polysaccharide.
The drying is conventional drying: any one of freeze drying, vacuum drying, spray drying, boiling drying or microwave drying.
A method of preparing a pharmaceutical composition for reducing the risk of ionizing radiation comprising the steps of:
(1) Pulverizing radix rehmanniae Preparata to obtain radix rehmanniae Preparata powder, soaking in water, decocting, separating filtrate, concentrating, and drying to obtain radix rehmanniae Preparata extract;
(2) Mixing radix rehmanniae Preparata extract with the rest components of Crystal orchid glycoside, neisseria sugar, radix Ophiopogonis polysaccharide, pachyman, pachymic acid, and schizandrin to obtain pharmaceutical composition.
The grain diameter of the prepared rehmannia root powder in the step (1) is 5-20 mesh sieve, and the mass-volume ratio of the prepared rehmannia root powder to water is 1:8-20, g/mL; mixing radix rehmanniae Preparata powder with water, soaking for 0.5-2 hr, decocting for 2-4 times, each for 1-2 hr, filtering the extractive solution, mixing filtrates, concentrating the filtrate, and drying to obtain radix rehmanniae Preparata extract.
Use of a pharmaceutical composition for reducing the risk of ionizing radiation in the manufacture of a medicament for reducing the risk of ionizing radiation.
A pharmaceutical composition for reducing the harm of ionizing radiation comprising said pharmaceutical composition and a pharmaceutically acceptable adjuvant; the dosage form of the medicine is any one of pills, tablets, capsules, granules, mixture or oral liquid in any pharmaceutically acceptable dosage form.
The medical acceptable auxiliary materials comprise starch, dextrin, sucrose, milk powder, sweetener, mannitol, lactose, cellulose and derivatives thereof, calcium carbonate, cyclodextrin, beta-cyclodextrin, phospholipid material, magnesium stearate, talcum powder, preservative or essence.
The beneficial effects of the invention are as follows:
1. on the basis of the formula of the ignition soup, the traditional Chinese medicine components and the active components of the formula are screened to obtain the composition containing the prepared rehmannia root, the crystal lanoside, the brown sugar, the ophiopogon root polysaccharide, the pachyman and the schizandrin, and the active components are mutually matched in a synergistic way, so that the composition can help organisms repair injury caused by ionizing radiation, promote recovery of a damaged hematopoietic system and an immune system, increase the number of peripheral blood leucocytes and reduce the micronucleus number of bone marrow cells. The pharmaceutical composition and the preparation thereof can effectively prevent and reduce the harm of ionizing radiation, and are beneficial to reducing the side effect of cancer radiotherapy.
2. The invention selects the main active components in the medicinal materials, has reasonable compatibility and synergistic effect, and can efficiently repair the body injury caused by ionizing radiation; the raw materials for preparing the composition by the optimized extraction method have high extraction rate of active ingredients and fully utilize medicinal material resources; the medicine composition prepared by adopting the specific method has definite composition components, can ensure stable and controllable quality and stable curative effect, is favorable for popularization and application, can be used for reducing side effects of tumor patients receiving radiotherapy and relieving the damage of ionizing radiation from various sources.
Detailed Description
In order to further clarify the characteristics of the present invention, a further explanation follows in connection with specific examples. It should be noted that the following examples are only preferred examples of the present invention, and not all examples are described in detail. Based on the following examples, one skilled in the art could make various changes and modifications to the present invention in light of the disclosure, which should also fall within the scope of the invention as claimed. In the following examples, unless otherwise specified, the operation methods used were conventional, the equipment used was conventional, the materials used in the respective examples were the same, and the preparation method was conventional and uniform. In the examples described below, the raw materials used were all commercially available products, and the water used was pure water.
The following non-limiting examples will enable those of ordinary skill in the art to more fully understand the invention and are not intended to limit the invention in any way. The following is merely exemplary of the scope of the invention as it is claimed and many variations and modifications of the invention will be apparent to those skilled in the art in light of the disclosure, which should be considered as falling within the scope of the invention as claimed.
Where numerical ranges are provided in the examples, it is understood that unless otherwise stated herein, both endpoints of each numerical range and any number between the two endpoints are significant both in the numerical range. Unless defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this invention belongs.
The present invention will be further illustrated by way of the following examples, in which various chemical reagents used, unless otherwise indicated, are commercially available. In the following examples and comparative examples, the crystal lanoside (formula C 16 H 22 O 11 CAS No: 5945-50-6), nernose (formula C 24 H 42 O 21 CAS No: 13133-07-8), pachymaran (CAS No. 65673-98-1), pachymaran (formula C) 33 H 52 O 5 CAS No: 29070-92-6), schizandrin (formula C) 24 H 32 O 7 CAS No: 7432-28-2), which is a processed product prepared by a processing method prescribed in the Chinese pharmacopoeia according to the dried root tuber of rehmannia glutinosa Libosch of Scrophulariaceae, the specific processing method has no influence on the technical effects, and the prepared rehmannia glutinosa Libosch used in examples and comparative examples is a commercially available product. The radix Ophiopogonis is dried root tuber of radix Ophiopogonis of Liliaceae, and has effects of nourishing yin, promoting salivation, moistening lung, clearing heart fire, and can be used for treating dry cough due to lung dryness, cough due to yin deficiency, sore throat, body fluid consumption thirst, internal heat diabetes, vexation, insomnia, and constipation due to intestinal dryness.
In the following embodiments, the preparation method of the ophiopogon polysaccharide comprises the following steps: pulverizing radix Ophiopogonis, sieving with 120 mesh sieve to obtain radix Ophiopogonis powder, mixing with 15 times of water, soaking for 1 hr, decocting at 95-100deg.C for 3 times, each time for 1 hr for extracting active substances, separating filtrate, concentrating, and drying to obtain radix Ophiopogonis polysaccharide.
Examples 1 to 5
A pharmaceutical composition for reducing the harm of ionizing radiation comprises the following components in parts by weight as shown in table 1:
table 1 Components in examples 1 to 5 and parts by weight thereof
| Parts by weight of | Example 1 | Example 2 | Example 3 | Example 4 | Example 5 |
| Prepared rehmannia root | 600 | 570 | 630 | 600 | 600 |
| Crystal orchid glycoside | 9 | 4 | 14 | 11 | 7 |
| Neisserial sugar | 22 | 17 | 27 | 26 | 18 |
| Radix Ophiopogonis polysaccharide | 70 | 60 | 80 | 70 | 70 |
| Pachyman | 85 | 75 | 95 | 80 | 90 |
| Poria acid | 3 | 1 | 5 | 2.4 | 3.6 |
| Schisandrin | 2 | 1 | 3 | 2 | 2 |
A method of preparing the pharmaceutical composition of examples 1-5 comprising the steps of:
(1) Pulverizing radix rehmanniae Preparata to obtain radix rehmanniae Preparata powder, sieving with 20 mesh sieve, mixing with water, soaking for 1 hr at a volume ratio of radix rehmanniae Preparata powder to water of 1:12, decocting for 3 times each for 1.5 hr, filtering the extractive solution, mixing filtrates, concentrating, and drying to obtain radix rehmanniae Preparata extract;
(2) Mixing radix rehmanniae Preparata extract with the rest components of Crystal orchid glycoside, neisseria sugar, radix Ophiopogonis polysaccharide, pachyman, pachymic acid, and schizandrin to obtain pharmaceutical composition.
Control extracts: the control extract is prepared according to the original recipe composition (three or two of rehmannia glutinosa, one or two of morinda officinalis and dwarf lilyturf tuber, two of north-flavor money and five of poria cocos) and comprises the following components in parts by weight: radix rehmanniae Preparata 600, radix Morindae officinalis 200, radix Ophiopogonis 200, north taste 40, poria 100. Pulverizing the above materials to obtain powder, sieving with 20 mesh sieve, mixing with water, soaking for 1 hr at a volume ratio of powder to water of 1:12, decocting for 3 times each for 1.5 hr, filtering the extractive solution, mixing filtrates, concentrating, and drying to obtain control extract.
Comparative example 1: the pharmaceutical composition comprises the following components in parts by weight: 600 parts of prepared rehmannia root extract, 9 parts of astragaloside, 22 parts of brown sugar, 70 parts of ophiopogon root polysaccharide, 85 parts of pachyman, 3 parts of pachymic acid and 2 parts of schizandrin.
The preparation method of the pharmaceutical composition is the same as in example 1.
The difference from example 1 is that the components of the pharmaceutical composition are changed, the crystal lanoside in the pharmaceutical composition is changed into astragaloside, and the rest components, parts by weight and preparation method of the pharmaceutical composition are the same as those of example 1.
Comparative example 2: the pharmaceutical composition comprises the following components in parts by weight: 600 parts of prepared rehmannia root extract, 9 parts of crystal orchid glycoside, 22 parts of sucrose, 70 parts of fructose, 85 parts of pachyman, 3 parts of pachymic acid and 2 parts of schizandrin. The preparation method of the pharmaceutical composition is the same as in example 1.
The difference from example 1 is that the components of the pharmaceutical composition are changed, and the Nernst, maidong and pachyman in the pharmaceutical composition are changed into sucrose, fructose and pachyman. The remaining components, parts by weight and preparation method of the pharmaceutical composition were the same as in example 1.
Comparative example 3: the pharmaceutical composition comprises the following components in parts by weight: 600 parts of prepared rehmannia root extract, 9 parts of crystal lanoside, 22 parts of Nernst sugar, 70 parts of ophiopogon root polysaccharide, 85 parts of pachyman, 3 parts of ferulic acid and 2 parts of schizandrin.
The difference from example 1 is that the components of the pharmaceutical composition are changed and the pachymic acid in the pharmaceutical composition is changed to ferulic acid. The remaining components, parts by weight and preparation method of the pharmaceutical composition were the same as in example 1.
Comparative example 4: the pharmaceutical composition comprises the following components in parts by weight: 600 parts of prepared rehmannia root extract, 9 parts of crystal lanoside, 22 parts of Nernst sugar, 70 parts of ophiopogon root polysaccharide, 85 parts of pachyman, 3 parts of pachyman acid and 2 parts of citric acid.
The difference from example 1 is that the components of the pharmaceutical composition are changed and the schizandrin in the pharmaceutical composition is changed to citric acid. The remaining components, parts by weight and preparation method of the pharmaceutical composition were the same as in example 1.
Efficacy evaluation test
The invention develops an efficacy evaluation test for reducing the damage of the ionizing radiation by the pharmaceutical composition, observes the influence of the pharmaceutical composition on the ionizing radiation damage model animal, and evaluates the effect of reducing the damage of the ionizing radiation.
Experimental method
Preparation methods of pharmaceutical compositions, control extracts of examples 1-5 and comparative examples 1-4:
1. the compositions of examples 1 to 5 and comparative examples 1 to 4 were mixed uniformly in parts by weight according to the components of examples 1 to 5 and comparative examples 1 to 4 in Table 1 to prepare powders. Preparing control extract according to the preparation method of control extract, and making into powder. When in use, the powder is dispersed with distilled water with equal amount, and is uniformly shaken when in use, and is preserved at 4 ℃. The compositions of examples 1-5, comparative examples 1-4, and the control extract were evaluated for their protective effect against ionizing radiation damage.
2. Experimental animals: healthy SPF-class female mice with the weight of 18 g-22 g are selected.
3. Modes of administration the pharmaceutical compositions of examples 1-5 comparative examples 1-4 and the control extract were administered at a dose of 1.2 g/kg. The test subjects were administered orally 1 time a day, after 28d of continuous gastric lavage, and then continued until the end of the experiment. The mice were perfused with a volume of 10mL/kg BW. Meanwhile, a model control group (0 mL/kgBW) is provided, sterile water is used for replacing the tested objects, and the daily gastric lavage volume is the same as that of each tested object group. Each group was given maintenance feed.
4. Evaluation test item
4.1 peripheral blood leukocyte count experiment in which the sample group was orally and continuously administered with the same dose of gamma rays once for whole body irradiation, and the irradiation dose was 3.0Gy (absorption dose rate 1.0Gy/60s, time 3 min). And respectively collecting 20 mu L of peripheral blood for three times before irradiation, 3d after irradiation and 14d after irradiation, adding into 0.38mL of 1% hydrochloric acid, uniformly mixing, adding into a blood cell counting plate, and calculating the total number of white blood cells in four large squares in a counting pool.
4.2 mouse bone marrow cell micronucleus experiments: the dose group was continuously administered with the test sample orally before and after irradiation, and the dose group and the radiation model control group were all irradiated once with the same dose of gamma rays throughout the body, and the irradiation dose was selected to be 3.0Gy (absorption dose rate 1.0Gy/60s, time 3 min). On the 3 rd day after irradiation, the animals were killed by cervical dislocation, the sternum was taken, and bone marrow fluid was squeezed out with hemostat and mixed with calf serum at one end of the slide, and the slide was conventionally smeared. After the smear is naturally dried, the smear is put into methanol for fixation for 10min, put into Giemsa application dye liquor for dyeing for 15min, immediately washed with distilled water and dried. Microscopic examination, each animal counted the number of micronuclei in 1000 multi-stained erythrocytes, micronuclei rate expressed in thousandths.
5. Statistical analysis
Statistical analysis is carried out on experimental data of each index by using statistical software SPSS29.0, and the data result uses mean number + -standard deviationThe comparison between groups is expressed by single factor analysis of variance (ANOVA), the comparison between two groups is expressed by LSD method, and p<0.05 is a difference ofStatistical significance.
2. Results
1. The results of the peripheral blood white cell count experiment are shown in table 2:
table 2 effect on the number of peripheral blood leukocytes of X-ray irradiated mice (n=10,)
note that: in contrast to the blank set of the cells, * ：p<0.05， ** ：p<0.01; in contrast to the set of models, # ：p<0.05， ## ：p<0.01; compared to example 1, +.: p is p<0.05，★★：p<0.01; compared to example 2: p is p<0.05，※※：p<0.01; in contrast to example 3, four: p is p<0.05，☆☆：p<0.01; in comparison with example 4, o: p is p<0.05，◇◇：p<0.01; in contrast to example 5, diamond-solid: p is p<0.05，◆◆：p<0.01
2. The results of the mouse bone marrow cell microassay are shown in Table 3:
table 3 effect on micronucleus rate of bone marrow cells of X-ray irradiated mice (n=10,)
note that: in contrast to the blank set of the cells, * ：p<0.05， ** ：p<0.01; in contrast to the set of models, # ：p<0.05， ## ：p<0.01；
compared to example 1, +.: p <0.05, +.: p <0.01; compared to example 2: p <0.05,: p <0.01; in contrast to example 3, four: p <0.05, > four: p <0.01; in comparison with example 4, o: p <0.05, <o: p <0.01; in contrast to example 5, diamond-solid: p <0.05, solid-of-solid: p <0.01
3. Conclusion(s)
The components in the compositions were sequentially replaced with other components in comparative examples 1 to 4. Since Astragalus has good protection effect on injury caused by radiotherapy, astragaloside as main active ingredient in Astragalus is adopted in comparative example 1 to replace Crystal lanoside in Morinda officinalis. The experimental results show that comparative example 1 is less effective than the examples and is comparable to the comparative examples. Because the resistant sugar is kestose and the monosaccharide species of the ophiopogon polysaccharide are mainly fructose and glucose, fructose and sucrose are used in comparative example 2 instead of the resistant sugar and ophiopogon polysaccharide, and pachyman, which is also a component in Poria, is used instead of pachyman. The experimental results show that comparative example 2 is less effective than the examples and is comparable to the comparative examples. The Chinese angelica has the function of replenishing blood, is also an important component of Chinese patent medicines for radiotherapy such as Shiquan Dabu decoction, eight delicacies decoction and the like, and the ferulic acid is an index component of the Chinese angelica, and the ferulic acid is adopted to replace the poria cocos acid in comparative example 3. The experimental results show that comparative example 3 is less effective than the examples and is comparable to the comparative examples. The active compounds in fructus Schisandrae mainly comprise lignin compounds (such as schizandrin) and organic acids (such as citric acid and malic acid). Thus, citric acid was used instead of schizandrin in comparative example 4. The experimental results show that comparative example 4 is less effective than the examples and is comparable to the comparative examples. Overall, the effect of the examples was superior to the control extract and the comparative example prepared according to the kindling decoction, and the effect of the comparative example and the control extract was equivalent. The effect of the comparative examples 1-4 on reducing body injury in irradiated mice was reduced compared to the examples, demonstrating that the individual components of the pharmaceutical compositions of the present invention are the best choice.
The pharmaceutical composition has the effect of reducing the harm of ionizing radiation; can effectively promote the recovery of blood systems, increase the number of peripheral blood leucocytes of irradiated mice, reduce the number of bone marrow cell micronuclei and reduce the damage condition of organism chromosomes. The medicine composition has definite components, reasonable compatibility and optimal curative effect.
Finally, it should be noted that the above description is only for illustrating the technical solution of the present invention, and not for limiting the scope of the present invention, and that the simple modification and equivalent substitution of the technical solution of the present invention can be made by those skilled in the art without departing from the spirit and scope of the technical solution of the present invention.
Claims (8)
1. The pharmaceutical composition for reducing the harm of ionizing radiation is characterized by comprising the following components in parts by weight: 570-630 parts of prepared rehmannia root, 4-14 parts of crystal lanoside, 17-27 parts of Nernst sugar, 60-80 parts of ophiopogon polysaccharide, 75-95 parts of pachyman, 1-5 parts of pachymic acid and 1-3 parts of schizandrin.
2. The pharmaceutical composition for reducing the risk of ionizing radiation according to claim 1, wherein the method for preparing the ophiopogon polysaccharide comprises the following steps: pulverizing radix Ophiopogonis to obtain radix Ophiopogonis powder with particle size of 120-180 meshes, soaking in water: the mass volume ratio of the dwarf lilyturf tuber powder to the water is 1:8-16 g/mL, soaking for 0.5-2h, decocting at 90-100deg.C for 2-4 times for 0.5-2h, separating filtrate, concentrating, and drying to obtain radix Ophiopogonis polysaccharide.
3. A pharmaceutical composition for reducing the risk of ionizing radiation according to claim 2, wherein the drying is conventional in the drying of: any one of freeze drying, vacuum drying, spray drying, boiling drying or microwave drying.
4. A method of preparing a pharmaceutical composition according to any one of claims 1 to 3, comprising the steps of:
(1) Pulverizing radix rehmanniae Preparata to obtain radix rehmanniae Preparata powder, soaking in water, decocting, separating filtrate, concentrating, and drying to obtain radix rehmanniae Preparata extract;
(2) Mixing radix rehmanniae Preparata extract with the rest components of Crystal orchid glycoside, neisseria sugar, radix Ophiopogonis polysaccharide, pachyman, pachymic acid, and schizandrin to obtain pharmaceutical composition.
5. The preparation method of claim 4, wherein the prepared rehmannia root powder in the step (1) has a particle size of 5-20 meshes, and the mass-volume ratio of the prepared rehmannia root powder to water is 1:8-20 g/mL; mixing radix rehmanniae Preparata powder with water, soaking for 0.5-2 hr, decocting for 2-4 times, each for 1-2 hr, filtering the extractive solution, mixing filtrates, concentrating the filtrate, and drying to obtain radix rehmanniae Preparata extract.
6. Use of a pharmaceutical composition according to any one of claims 1-3 for the preparation of a medicament for reducing the risk of ionizing radiation.
7. A medicament, characterized in that: an active ingredient comprising the pharmaceutical composition of any one of claims 1 to 3.
8. A medicament according to claim 7, characterized in that: comprises the pharmaceutical composition and pharmaceutically acceptable auxiliary materials; the dosage form of the medicine is any one of pills, tablets, capsules, granules, mixture or oral liquid in any pharmaceutically acceptable dosage form.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311415105.9A CN117205266A (en) | 2023-10-29 | 2023-10-29 | Pharmaceutical composition for reducing ionizing radiation hazard |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202311415105.9A CN117205266A (en) | 2023-10-29 | 2023-10-29 | Pharmaceutical composition for reducing ionizing radiation hazard |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN117205266A true CN117205266A (en) | 2023-12-12 |
Family
ID=89035544
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202311415105.9A Pending CN117205266A (en) | 2023-10-29 | 2023-10-29 | Pharmaceutical composition for reducing ionizing radiation hazard |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN117205266A (en) |
-
2023
- 2023-10-29 CN CN202311415105.9A patent/CN117205266A/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104306959A (en) | Medicine composition for treating osteoporosis and preparation method thereof | |
| CN101607059A (en) | The application of a kind of Chinese medicine composition in the medicine of preparation treatment and prevention radiation injury | |
| CN102861193B (en) | Traditional Chinese medicine composition for treating gastric cancer | |
| CN113663029A (en) | Compound wild buckwheat rhizome composition | |
| CN102078569A (en) | Traditional Chinese medicine preparation for treating liver cancer and preparation method thereof | |
| CN102247479A (en) | Antitumor strong medicine and preparation method thereof | |
| CN111298123A (en) | Antiviral composition and application thereof in resisting human influenza virus and avian influenza virus | |
| CN117205266A (en) | Pharmaceutical composition for reducing ionizing radiation hazard | |
| CN114712478B (en) | Traditional Chinese medicine composition for treating intestinal diseases, preparation and preparation method thereof | |
| CN108126011B (en) | Pharmaceutical composition for auxiliary conditioning of patients undergoing tumor radiotherapy and chemotherapy and preparation method thereof | |
| CN101259180B (en) | Shenshe composition and preparation thereof | |
| CN102552377A (en) | Anti-radiation damage medicine | |
| CN105521246A (en) | Medicinal preparation for treating lung cancer and applications of medicinal preparation | |
| CN100382818C (en) | Prepn process of Chinese medicine and its coated tablet for treating cystic mastoproliferation and mastitis | |
| CN104998085A (en) | Chinese herbal compound composition capable of enhancing immune function and preparation method thereof | |
| CN116688053B (en) | Traditional Chinese medicine composition for improving tumour cachexia and muscular atrophy, preparation method and application | |
| CN114588240B (en) | Traditional Chinese medicine composition for treating colorectal cancer and preparation method and application thereof | |
| CN114404490B (en) | Traditional Chinese medicine for treating leucopenia after tumor radiotherapy and chemotherapy and preparation method | |
| CN101239167B (en) | Medicaments for treating hysteromyoma | |
| CN106421487B (en) | A kind of Chinese medicine composition and its preparing the application for the treatment of medicine in terms of skin injury after chemicotherapy | |
| CN112022944A (en) | Anticancer Chinese medicinal composition | |
| CN106943506B (en) | A pharmaceutical composition for treating climacteric syndrome, and its preparation method | |
| CN105726969A (en) | Traditional Chinese medicine for treating acute radiation pneumonitis and preparation method of traditional Chinese medicine | |
| CN104189846A (en) | Traditional Chinese medicine composition used as radiotherapy and chemotherapy sensitizing agent and preparation method thereof | |
| CN105687715B (en) | Traditional Chinese medicine composition for treating chronic benzene poisoning thrombopenia and leukopenia |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination |